Intuitive Surgical, Inc.

LSE:0R29 Stock Report

Market Cap: US$191.9b

Intuitive Surgical Valuation

Is 0R29 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0R29 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0R29 ($537.47) is trading above our estimate of fair value ($322.44)

Significantly Below Fair Value: 0R29 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0R29?

Key metric: As 0R29 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0R29. This is calculated by dividing 0R29's market cap by their current earnings.
What is 0R29's PE Ratio?
PE Ratio85.6x
EarningsUS$2.24b
Market CapUS$191.92b

Price to Earnings Ratio vs Peers

How does 0R29's PE Ratio compare to its peers?

The above table shows the PE ratio for 0R29 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average43.1x
SN. Smith & Nephew
35.3x22.7%UK£8.6b
NIOX NIOX Group
22.9x15.8%UK£251.5m
SYK Stryker
39.2x11.6%US$141.3b
BSX Boston Scientific
75.2x21.4%US$134.2b
0R29 Intuitive Surgical
85.6x11.4%US$191.9b

Price-To-Earnings vs Peers: 0R29 is expensive based on its Price-To-Earnings Ratio (85.6x) compared to the peer average (43.1x).

Price to Earnings Ratio vs Industry

How does 0R29's PE Ratio compare vs other companies in the European Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
0R29 85.6xIndustry Avg. 30.2xNo. of Companies10PE01632486480+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0R29 is expensive based on its Price-To-Earnings Ratio (85.6x) compared to the European Medical Equipment industry average (30.2x).

Price to Earnings Ratio vs Fair Ratio

What is 0R29's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0R29 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio85.6x
Fair PE Ratio48.3x

Price-To-Earnings vs Fair Ratio: 0R29 is expensive based on its Price-To-Earnings Ratio (85.6x) compared to the estimated Fair Price-To-Earnings Ratio (48.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0R29 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$537.47
US$556.42
+3.5%
14.3%US$650.00US$265.00n/a27
Dec ’25US$542.00
US$536.43
-1.0%
12.8%US$643.00US$265.00n/a26
Nov ’25US$506.56
US$529.70
+4.6%
12.0%US$604.00US$265.00n/a26
Oct ’25US$486.32
US$486.45
+0.03%
12.2%US$586.00US$265.00n/a26
Sep ’25US$489.07
US$482.03
-1.4%
12.4%US$586.00US$265.00n/a26
Aug ’25US$448.01
US$469.35
+4.8%
11.0%US$525.00US$265.00n/a25
Jul ’25US$435.65
US$426.49
-2.1%
11.2%US$500.00US$253.00n/a25
Jun ’25US$398.65
US$423.57
+6.3%
11.0%US$500.00US$253.00n/a25
May ’25US$372.11
US$420.59
+13.0%
10.5%US$475.00US$253.00n/a25
Apr ’25US$399.11
US$414.11
+3.8%
10.5%US$475.00US$253.00n/a25
Mar ’25US$397.82
US$408.45
+2.7%
12.1%US$475.00US$230.00n/a25
Feb ’25US$383.54
US$402.75
+5.0%
13.9%US$475.00US$230.00n/a25
Jan ’25US$337.72
US$337.19
-0.2%
13.2%US$400.00US$230.00n/a25
Dec ’24US$314.51
US$326.63
+3.9%
12.7%US$400.00US$230.00US$542.0025
Nov ’24US$267.02
US$324.90
+21.7%
12.8%US$400.00US$230.00US$506.5624
Oct ’24US$292.59
US$361.91
+23.7%
10.5%US$400.00US$230.00US$486.3223
Sep ’24US$309.51
US$361.91
+16.9%
10.5%US$400.00US$230.00US$489.0723
Aug ’24US$323.26
US$361.91
+12.0%
10.5%US$400.00US$230.00US$448.0123
Jul ’24US$342.94
US$310.48
-9.5%
10.5%US$365.00US$204.00US$435.6521
Jun ’24US$308.58
US$308.19
-0.1%
10.1%US$365.00US$204.00US$398.6521
May ’24US$301.26
US$305.24
+1.3%
9.6%US$350.00US$204.00US$372.1121
Apr ’24US$254.82
US$271.48
+6.5%
11.5%US$325.00US$204.00US$399.1121
Mar ’24US$227.24
US$273.80
+20.5%
12.3%US$325.00US$204.00US$397.8220
Feb ’24US$245.92
US$273.80
+11.3%
12.3%US$325.00US$204.00US$383.5420
Jan ’24US$267.82
US$271.05
+1.2%
14.7%US$325.00US$204.00US$337.7221
Dec ’23US$274.42
US$260.30
-5.1%
13.8%US$325.00US$204.00US$314.5120

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 10:02
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Intuitive Surgical, Inc. is covered by 59 analysts. 30 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
null nullArgus Research Company
Richard PurkissAtlantic Equities LLP